MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.metabol.2024.155958

Медицинская библиотека · Metabolism: clinical and experimental · 2024

Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019.

Danpanichkul Pojsakorn, Suparan Kanokphong, Dutta Priyata, Kaeosri Chuthathip, Sukphutanan Banthoon, Pang Yanfang, Kulthamrongsri Narathorn, Jaisa-Aad Methasit, Ng Cheng Han, Teng Margaret, Nakano Masahito, Morishita Asahiro, Alkhouri Naim, Yang Ju Dong, Chen Vincent L, Kim Donghee, Fallon Michael B, Diaz Luis Antonio, Arab Juan Pablo, Mantzoros Christos S, Noureddin Mazen, Lazarus Jeffrey V, Wijarnpreecha Karn

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic conditions affect populations across economic strata. Nevertheless, there are limited epidemiological studies addressing these diseases in low (LICs) and lower-middle-income countries (lower MICs). Therefore, an analysis of the trend of MASLD and cardiometabolic conditions in these countries is necessary.

METHODS

From 2000 to 2019, jointpoint regression analysis was employed to calculate the prevalence, mortality, and disability-adjusted life years (DALYs) for cardiometabolic conditions including MASLD, type 2 diabetes mellitus (T2DM), dyslipidemia (DLP), hypertension (HTN), obesity, peripheral artery disease (PAD), atrial fibrillation and flutter (AF/AFL), ischemic heart disease (IHD), stroke, and chronic kidney disease from HTN and T2DM, in LICs and lower MICs (according to the World Bank Classification 2019) using the Global Burden of Disease 2019 data.

RESULTS

Among the eleven cardiometabolic conditions, MASLD (533.65 million), T2DM (162.96 million), and IHD (76.81 million) had the highest prevalence in LICs and Lower MICs in 2019. MASLD represented the largest proportion of global prevalence in these countries (43 %). From 2000 to 2019, mortality in LICs and lower MICs increased in all cardiometabolic conditions, with obesity-related mortality having the highest increase (+134 %). During this timeframe, there were increased age-standardized death rates (ASDR) from obesity, PAD, and AF/AFL. From all conditions, the DALYs-to-prevalence ratio was higher in LICs and lower MICs than the global average.

CONCLUSION

The burden of MASLD and cardiometabolic conditions is increasing worldwide, with LICs and lower MICs experiencing higher (DALYs) disability per prevalence. As these conditions are preventable, counteracting these trends requires not only the modification of ongoing actions but also the strategizing of immediate interventions.

Для цитирования: Danpanichkul Pojsakorn, Suparan Kanokphong, Dutta Priyata, Kaeosri Chuthathip, Sukphutanan Banthoon, Pang Yanfang, Kulthamrongsri Narathorn, Jaisa-Aad Methasit, Ng Cheng Han, Teng Margaret, Nakano Masahito, Morishita Asahiro, Alkhouri Naim, Yang Ju Dong, Chen Vincent L, Kim Donghee, Fallon Michael B, Diaz Luis Antonio, Arab Juan Pablo, Mantzoros Christos S, Noureddin Mazen, Lazarus Jeffrey V, Wijarnpreecha Karn. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019.. Metabolism: clinical and experimental. 2024. DOI: 10.1016/j.metabol.2024.155958.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.